becoming the first-line therapy for some types of cancer. Their mechanism of action is based on the ability to regulate the immune system or by interacting with targets that are either overexpressed in tumor cells, released into the extracellular...
using ATP, disrupting the electrochemical gradient. Senescent cells display a more polarized state than normal cells, making them more susceptible to the effects of cardiac glycosides. Administration of digoxin can effectively remove senescent pulmonary fibroblasts in a pulmonary fibrosis mouse model [214...
Formulary Definition, Management & Uses Therapeutic Equivalence | Overview, Criteria & Codes 7:42 Therapeutic Interchange Programs: Definition & Application Next Lesson Designing a Medication Use Evaluation Analyzing Medication Use Evaluation Data Ch 11. CPJE Exam FlashcardsTherapeutic...
This study evaluated the analytical performance of the Atellica IM Digoxin (Dig), and the Atellica CH Lithium_2 (LITH_2) Assays on the Atellica CI Analyzer.Methods Precision studies were performed according to CLSI EP05-A3 using native and contrived human serum samples. One aliquot of each ...
Diagnostic probes to detect senescence (‘Senoprobes’) with considerable preclinical specificity have been created190,191,192. The predominant subtype currently uses the increased lysosomal SA-β-Gal activity in senescence to induce a detectable and sometimes clinically relevant signal. ...
using ATP, disrupting the electrochemical gradient. Senescent cells display a more polarized state than normal cells, making them more susceptible to the effects of cardiac glycosides. Administration of digoxin can effectively remove senescent pulmonary fibroblasts in a pulmonary fibrosis mouse model [214...
The invention discloses therapeutic methods and uses of certain steroidal sapogenins, related compounds and derivatives thereof, in the treatment of non-cognitive neurodegeneration, non-cognitive neuromuscular degeneration, motor-sensory neurodegeneration or receptor dysfunction or loss in the absence of cognit...
a protein or ribonucleoprotein complex domain, a protein domain, or substantially all of a protein sequence. In other instances, e.g. haptens, the epitope can be a very small molecule, e.g. digoxin, digoxigenin, etc. Autoantibodies are also well established to bind complexes of proteins, ...
The antibodies are capable of inhibiting the growth of human tumor cells expressing human epidermal growth factor receptors. Therapeutic uses of these monoclonal antibodies by themselves and in combination with anti-neoplastic agents are also disclosed. ...
The present invention relates to methods for reducing the risk of major adverse cardiovascular events in type 2 diabetes mellitus (T2DM) patients with multiple cardiovascular risk f